NF-κB-IN-12

Cat. No.: HY-149580: FAQs
Data Sheet Handling Instructions

Molarity Calculator

NF-κB-IN-12 (compound 3h) is a potent NF-κB inhibitor, with an IC₅₀ of 1.02 μM. NF-κB-IN-12 can be used for acute lung injury research.

For research use only. We do not sell to patients.

NF-κB-IN-12 Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

NF-κB-IN-12 (compound 3h) is a potent NF-κB inhibitor, with an IC₅₀ of 1.02 μM. NF-κB-IN-12 can be used for acute lung injury research^[1].

IC₅₀ & Target

IC50: 1.02 ± 0.29 μM (NF-κB)^[1]

In Vitro

NF-κB-IN-12 (compound 3h) is non-toxic to MCF-12A cells (normal epithelial cells)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NF-κB-IN-12 (compound 3h) (5-10 mg/kg, IP, daily) shows a protective effect in SD rats against sepsis induced by the CLP (cecal ligation puncture) method^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) rats (male, 7-9 weeks old, weighing 210-260 g)^[1]
Dosage:	5, 10 mg/kg
Administration:	IP, daily for 3 days before CLP surgery and on the 4th day 1 h before CLP
Result:	Significantly upregulated SOD and GSH. Improved the antioxidant status of experimental rats. Reduced the elevated level of nuclear NF-ĸB. Caused a significant reduction in lung edema and total proteins, mononuclear leukocytes, and polymorphonuclear leukocytes in BALF (bronchoalveolar lavage fluid).

Molecular Weight

582.63

Formula

C₃₀H₂₆N₆O₅S

SMILES

O=C(N1N=CC(C2=CC=C(S(=O)(C3=CC=C(O)C=C3)=O)C=C2)C1C4=CC=C(OC)C=C4)C5=CN6C(C(NC)=NC=C6)=N5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Zang B, et al. Synthesis and protective effect of pyrazole conjugated imidazo[1,2-a]pyrazine derivatives against acute lung injury in sepsis rats via attenuation of NF-κB, oxidative stress, and apoptosis. Acta Pharm. 2023 Sep 14;73(3):341-362. [Content Brief]

NF-κB-IN-12 Related Classifications

Inflammation/Immunology

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NF-κB-IN-12NF-κBNuclear factor-κBNuclear factor-kappaBMCF-12Aanti-inflammatorysepsisacute lung injuryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks